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Background: HIV-infected patients on antiretroviral therapy frequently develop dyslipidemias and, despite therapy
with potent lipid-lowering agents, a high percentage does not achieve guideline recommended lipid targets. In this
study, we examined the efficacy of combination treatment with a statin and the cholesterol transport blocker,
ezetimibe, vs. monotherapy with a statin in HIV-infected patients not achieving lipid goals.
Methods: This was a 12-week, prospective, randomized, open-label clinical trial. Patients were eligible if they had
an apolipoprotein B (apoB) >0.80 g/L despite therapy with rosuvastatin 10 mg daily for a minimum of 12 weeks.
Patients were randomized to take ezetimibe 10 mg/rosuvastatin 10 mg or rosuvastatin 20 mg for 12 weeks. Percentage
and absolute change in apoB (primary outcome), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC),
triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, apoliporpotein A1 (apoA1), apoB/apoA1, TC/
HDL-C, atherogenic index of plasma (API), and high-sensitivity C-reactive protein (hsCRP) were compared. Changes in
safety parameters (such as AST, ALT, CK) and clinical symptoms were also assessed.
Results: Forty-three patients (23 on ezetimibe 10 mg/rosuvastatin 10 mg and 20 on rosuvastatin 20 mg) completed
the trial. Baseline characteristics did not differ between the groups. Significant improvements in apoB were seen with
both ezetimibe plus rosuvastatin (mean of -0.17 g/L, p < 0.001) and rosuvastatin 20 mg (mean of -0.13 g/L, p = 0.03)
treatment groups, but did not differ between groups (p = 0.53). Significant between-group differences were observed
for mean TC (-1.01 mmol/L vs. -0.50 mmol/L, p = 0.03), TG (-0.62 mmol/L vs -0.17 mmol/L, p = 0.03), and non-HDL-C
(-0.97 mmol/L vs. -0.53 mmol/L, p = 0.03) all in favour of the ezetimibe plus rosuvastatin group. Two patients, both in
the rosuvastatin 20 mg group, experienced mild myalgias; neither discontinued the study.
Conclusions: The addition of ezetimibe to rosuvastatin appears to be safe in patients with HIV. Furthermore, the
combination of ezetimibe and rosuvastatin improved TG, AIP and non-HDL cholesterol levels more than a dose increase
in rosuvastatin in patients with HIV-associated dyslipidemia.
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Human immunodeficiency virus (HIV)-associated dys-
lipidemia is becoming more common with the extensive
use of antiretroviral therapy (ART) resulting in an in-
crease in incidence of atherosclerotic cardiovascular
disease (ASCVD) [1–6].
Statins have been widely used for prevention of ASCVD
[7]. Increasing numbers of individuals with HIV-associated
dyslipidemia are receiving statins for secondary prevention
of ASCVD [8]; many HIV-infected patients receiving statin
therapy do not achieve recommended treatment goals [9].
Furthermore, treatment of HIV-associated dyslipidemia is
further complicated by altered statin metabolism and drug
interactions with antiretroviral medications both of which
increase the risk of statin induced myopathy [9]. Few stud-
ies have examined the effect of alternative lipid-lowering
agents in HIV-infected patients.
Ezetimibe, an inhibitor of intestinal cholesterol absorp-
tion, has been used as a second-line therapy for patients
who are unable to tolerate high dose statins or in those
who do not achieve therapeutic lipid target levels [10].
In HIV-dyslipidemia, ezetimibe is safe and can be used
in patients with poor response to statins and those re-
ceiving protease inhibitors [10–14].
Rosuvastatin is a relatively new statin, which is not
metabolised by the cytochrome P 3A4 (CYP3A4) enzyme
system. As CYP3A4 is often enzyme-inhibited by certain
ART therapies, rosuvastatin is preferred in the treatment
of ART-associated dyslipidemia. A limited number of trials
have assessed the efficacy of rosuvastatin in patients with
HIV with all reporting a favorable decline in some of lipid
parameters [8, 15–18]. The aim of the current study was
to assess whether HIV-infected patients treated with a
combination of rosuvastatin 10 mg plus ezetimibe 10 mg
show a greater improvement in their lipid profile com-
pared to an increased dose of rosuvastatin (from 10 to
20 mg). Several studies in non-HIV populations have
shown that co-administration of rosuvastatin plus ezeti-
mibe is safe, and achieved significant improvements in
lipid profiles in high-risk patients compared to monother-
apy [10].
Methods
This prospective, randomized, open-label study was car-
ried out in HIV-infected patients seen at the Immunodefi-
ciency Clinic (IDC)-HIV metabolic Clinic at St. Paul’s
Hospital, Vancouver, BC, Canada. We compared the effi-
cacy and safety of co-administration of 10 mg rosuvastatin
and 10 mg of ezetimibe versus 20 mg of rosuvastatin over
a 15 months period. The protocol and informed consent
were approved by the institutional Ethics Board (Univer-
sity of British Columbia).
Patients included in this study were men and women
age ≥ 19 years with apolipoprotein B (apoB) >0.8 g/L,maintained on stable dose of rosuvastatin 10 mg for the
past 12 weeks and on a stable background of ART for
the 12 weeks prior to study. Patients continued the same
ART for the subsequent 12 weeks of study.
Main exclusion criteria included serum aspartate ami-
notransferase (AST) or alanine aminotransferase (ALT)
elevations ≥3-fold upper limit of normal (ULN), serum
creatine kinase (CK) concentration elevation ≥10-fold
ULN, previous adverse reaction to ezetimibe, recent use
of ezetimibe (within 30 days of starting the study), a his-
tory of significant myopathy or rhabdomyolysis with any
statin, current use of gemfibrozil (Lopid), niacin/nico-
tinic acid, colestipol (Colestid), cholestyramine (Novo-
Cholamine), or any agent with a potential drug-drug
interaction, pregnant or breastfeeding woman or expect-
ing to conceive or donate eggs during the study; males
planning to impregnate a woman or provide sperm do-
nation during the study; use of excessive (more than one
drink a day for a woman and two drinks for a man)
amounts of alcohol or recreational drugs; or previous or
current liver disease.
Patients were randomized in a 1:1 ratio to either an in-
creased daily dose of rosuvastatin to 20 mg, or to 10 mg
ezetimibe added on to their current 10 mg rosuvastatin
daily dose. Serum samples were obtained and analyzed
at the baseline and after 12 weeks of treatment for lipid
profile, safety and inflammatory parameters. Also, at the
end of the study (12 weeks) participants were asked
questions regarding side effects (such as myalgia and
gastrointestinal side effects).
The primary outcome was the percent change in
serum apoB, between participants treated with rosuvas-
tatin 20 mg versus participants treated with ezetimibe
10 mg plus rosuvastatin 10 mg. Even though, calculated
or measured LDL-C concentration has been known as
the major goal of lipid lowering therapies, many individ-
uals may experience progression of atherosclerosis or
cardiovascular events despite having ideal LDL-C con-
centrations. Barter et al have shown that predicting the
future CVD is best reflected by apoB concentration [19].
ApoB, which measures numbers of atherogenic particles
in plasma, is superior to LDL-C not only as an index of
cardiovascular risk but also as a guide to the adequacy
of lipid lowering therapy. Secondary outcomes included
the percent and absolute change in serum concentra-
tions of low-density lipoprotein cholesterol (LDL-C),
total cholesterol (TC), triglycerides (TG), high-density
lipoprotein cholesterol (HDL-C), TC/ HDL, non- HDL-
C, apolipoprotein A1 (apoAI), apoB/apoAI, atherogenic
index of plasma (AIP), fasting blood glucose (FBG), and
high-sensitivity C-reactive protein (hsCRP) between par-
ticipants treated with rosuvastatin alone versus partici-
pants treated with rosuvastatin and ezetimibe. Further
secondary endpoints included within group changes in
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eters, specifically incidence of complications as mea-
sured by an increase in AST and/or ALT ≥3-fold ULN
and a CK ≥10-fold ULN in participants treated with
rosuvastatin 20 mg versus participants treated with eze-
timibe 10 mg plus rosuvastatin10 mg.
For the primary outcome, with a sample size of 50 pa-
tients planned for randomization, the study was anticipated
to have at least 90 % power to demonstrate a difference be-
tween ezetimibe co-administrated with rosuvastatin and
the comparative increased dose rosuvastatin monotherapy,
assuming a reduction of apoB of 0.25 g/L, a SD of 0.27 g/L
(the type one error of 0.05 and type two error of 0.1).
Statistical analysis
Data are expressed as mean ± SD. Assumptions of
normality were tested by Shapiro-Wilks tests and review
of plots. The primary analysis was to compare treatment
effects between groups. For variables with a symmetrical
distribution, analysis of covariance (ANCOVA) adjusted
for baseline values were used. For variables with skewed
distributions, between-treatment changes from baseline
were compared with Mann-Whitney U tests. The sec-
ondary analysis was to compare changes within each
group with paired t-tests or Wilcoxon rank-sum tests, asTable 1 Baseline characteristics of the study subjects*
Characteristic Ezetimibe add-
Age, years† 56.5 ± 7.4
Male sex 22 (95.6)
Caucasian 19 (82.6)
Duration of ARV therapy (months)† 24 (16–34)
CD4+ cell count (cells/mm3)† 580.0 ± 193





Antihypertensive agents 13 (56.5)
Current Smoker 6 (26.1)
Previous Smoker§ 8 (34.8)
Diabetes Mellitus 8 (34.8)
Hypertension 13 (56.5)
Family History of CVD 10 (43.5)
Body Mass Index (kg/m2)† 26.0 ± 4.2
Waist Circumference, cm† 98 ± 13.7
*Data are frequency (%) unless otherwise indicated
†Data are mean (±SD)
‡ < 40 copies/mL
§ less than one year of smoking cessation prior to study recruitment
ARV, antiretroviral; VL, viral load; PI, protease inhibitor; NNRTI, non-nucleoside
reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase; CVD, cardiovaappropriate. Calculations were performed using com-
puter software (SPSS/Mac v. 19.0.0).
Any patients who did not return for the 12-week visit
were excluded from the analysis except those who had
withdrawn for reason of intolerance or toxicity. These
patients were considered not to have changed from
baseline if they did not appear for their follow-up visit.
The proportion of patients who have experienced an in-
crease in AST and ALT ≥3-fold ULN or a CK ≥10-fold
ULN were compared between treatment groups using
the Fisher’s exact test.
Results
Patient demographics and baseline characteristics
Due to slow enrollment accrual only 46 patients were
randomized and 43 patients (23 rosuvastatin plus ezeti-
mibe, 20 rosuvastatin) completed the 12 week study.
Three patients out of 46 patients were excluded, 2 due
to elevated liver enzymes and one due to complaints of
muscle soreness. Baseline characteristics of the study
population are summarized in Table 1. There were no
differences between groups in terms of age or clinical
characteristics of HIV. However, despite randomization,
there were some observable differences between groups
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more were current smokers whereas more patients in
the rosuvastatin group self-identified as past smokers
(quit within the last 12 months). Baseline lipid and
lipoprotein levels were similar between the two groups
(Table 2).
Effects of adding ezetimibe to rosuvastatin or increasing
rosuvastatin dose on metabolic parameters
The primary and secondary endpoints are displayed in
Table 3. Twelve weeks of treatment with either rosuvas-
tatin 20 mg or rosuvastatin 10 mg plus ezetimibe 10 mg
significantly decreased TC, LDL, TC/HDL, and apoB.
Also, addition of ezetimibe to rosuvastatin resulted in
significant improvements in TG, non-HDL-C, apoB/
apoAI, and AIP. The improvement in TC and TG was
significantly greater with ezetimibe 10 mg plus rosuvas-
tatin 10 mg than with rosuvastatin 20 mg alone.
Ezetimibe 10 mg plus rosuvastatin 10 mg and rosuvas-
tatin 20 mg monotherapy were generally well tolerated
during this 12 week study. Two patients in the rosuvas-
tatin monotherapy group experienced myalgias with one
of them experiencing moderate to severe cramping.
Neither of these two patients discontinued the study
medication. A statistically significant increase in ALT
was observed in the ezetimibe plus rosuvastatin group
but this increase was small and not likely to be clinic-
ally relevant.Table 2 Baseline values for primary and secondary outcomes
Ezetimibe add- on grou
ApoB, g/L 1.06 ± 0.24
ApoA1, g/L 1.54 ± 0.27
ApoB:ApoA1 0.69 ± 0.21
TC, mmol/L 5.23 ± 1.06
LDL, mmol/L 2.80 ± 0.93
HDL, mmol/L 1.21 ± 0.29
TC:HDL 4.92 ± 2.25
TG, mmol/L 2.55 ± 1.32
AIP 0.29 ± 0.33
Non-HDL-C, mmol/L 4.04 ± 1.05
Glucose, mmol/L 6.54 ± 1.84
hsCRP, mg/L 5.6 ± 10.20
Creatinine, μmol/L 91 ± 22.50
ALT, U/L 33 ± 13.80
AST, U/L 29 ± 11.0
CK, U/L 142 ± 100.0
Data are given as mean (±SD)
apoB, apolipoprotein B; apoA1,apolipoprotein A1;TC, total cholesterol; LDL-C, low-d
triglycerides; AIP, atherogenic index of plasma; FBG, fasting blood glucose; hsCRP, h
aminotransferase; CK, creatine kinaseSub-analysis was carried out to determine the propor-
tion of patients reaching primary (LDL-C ≤2.0 mmol/L,
50 % reduction in LDL-C, ApoB ≤0.80 g/L, or non-
HDL-C ≤2.6) or secondary (TG <1.7 mmol/L, ApoB:A-
poA1 ratio <0.80, hsCRP <2 mg/L) high cardiovascular
risk targets [20] as well as the high risk limit for AIP
(<0.21) [21]. As illustrated in Table 4, both treatment
regimens resulted in an increased proportion of patients
reaching primary and secondary targets with the excep-
tion of hsCRP, which showed no improvement in the
ezetimibe plus rosuvastatin group.
Discussion
The primary findings of this study is that rosuvastatin10
mg/ezetimibe 10 mg combination had a greater effect on
lowering non-HDL-C, TG, and AIP as compared to
rosuvastatin 20 mg monotherapy. This trial is the first
study to evaluate and compare the efficacy and safety of
ezetimibe and rosuvastatin 10 mg versus rosuvastatin
20 mg in HIV-infected patients.
This study showed that both ezetimibe 10 mg plus
rosuvastatin 10 mg and rosuvastatin 20 mg significantly
reduced LDL-C. Addition of ezetimibe 10 mg to rosu-
vastatin 10 mg had a greater impact on lowering LDL-C
than rosuvastatin 10 mg monotherapy (22.5 % reduction
vs. 16.5 % reduction, respectively). The magnitude of
changes in LDL-C in our study was similar to other
studies done in HIV populations where eztimibe was co-

















ensity lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; TG,
igh-sensitivity C-reactive protein; AST, aspartate aminotransferase; ALT, alanine
Table 3 Effects of adding ezetimibe to rosuvastatin or increasing rosuvastatin dosage on lipid and metabolic outcomes
Values after 12 weeks Change after 12 weeks P Value (Difference










ApoB, g/L 0.89 ± 0.25 0.88 ± 0.22 −0.17 ± 0.18* −0.13 ± 0.25* 0.53
ApoA1, g/L 1.47 ± 0.26 1.56 ± 0.30 −0.07 ± 0.25 −0.05 ± 0.24 0.15
ApoB:ApoA1 0.55 ± 0.29 0.60 ± 0.23 −0.15 ± 0.29* −0.12 ± 0.33 0.81
TC, mmol/L 4.23 ± 1.03 4.56 ± 0.75 −1.01 ± 0.79* −0.50 ± 0.63* 0.03
LDL, mmol/L 2.12 ± 0.63 2.07 ± 0.46 −0.68 ± 0.54* −0.48 ± 0.55* 0.37
HDL, mmol/L 1.21 ± 0.27 1.31 ± 0.48 −0.00 ± 0.29 0.03 ± 015 0.72
TC:HDL 3.29 ± 1.41 3.73 ± 0.92 −1.63 ± 2.86* −0.52 ± 0.65* 0.09
TG, mmol/L 1.92 ± 0.98 2.88 ± 1.42 −0.62 ± 0.58* −0.17 ± 0.57 0.03
AIP 0.16 ± 0.30 0.30 ± 0.38 −0.12 ± 0.20* −0.03 ± 0.12 0.13
Non-HDL-C, mmol/L 3.06 ± 0.98 3.25 ± 0.71 −0.97 ± 0.68* −0.53 ± 0.13 0.03
FBG, mmol/L 6.87 ± 2.49 5.82 ± 1.29 0.34 ± 1.28 −0.34 ± 1.75 0.15
hsCRP, mg/L 5.19 ± 7.25 1.72 ± 1.87 −0.60 ± 12.5 −1.06 ± 3.48 0.87
Creatinine, μmol/L 98 ± 58 151 ± 265 8 ± 48 53 ± 258 0.43
ALT, U/L 42 ± 22 34 ± 15 9 ± 17* 1.28 ± 16.6* 0.18
AST, U/L 32 ± 21 29 ± 8 4 ± 14 −0.10 ± 8 0.30
CK, U/L 126 ± 63 189 ± 103 −20 ± 90 12 ± 69 0.23
Data are given as mean (±SD)
*Significant change from their baseline (p < 0.05)
apoB, apolipoprotein B; apoA1,apolipoprotein A1;TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; TG,
triglycerides; API, atherogenic index of plasma; FBG, fasting blood glucose; hsCRP, high-sensitivity C-reactive protein; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; CK, creatine kinase
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of changes in LDL-C between studies may be due to
other factors such as age of participants, type and dose
of statin, type of ART, or other medications. Overall, the
percent reduction in LDL-C in our study and studies in-
volving HIV-infected patients is not as high as in studies
involving non-HIV infected patients. In non-HIV studies
with ezetimibe added on therapy LDL-C was decreased by
25-60 % [10]. This suggests that HIV-infected patients are
less affected by this therapy. The 2012 Canadian Cardio-
vascular Society (CCS) guidelines for the general popula-
tion have recommended a 50 % reduction in LDL-C from
baseline or LDL < 2.0 mmol/L as the target levels for the
treatment of moderate and high risk patients [20]. In our
center, we treat HIV- positive patients at the moderate risk
lipid profile targets. While ezetimibe administration wasTable 4 Primary and secondary targets 12 weeks after treatment wi
Primary Targets
LDL-C ≤2.0 mmol/L 50 % reduction
in LDL
ApoB ≤0.80
Rosuvastatin 20 mg 2.07 19 % reduction 0.88
Rosuvastatin 10 mg +
Ezetimibe 10 mg
2.12 24 % reduction 0.89
LDL-C, low-density lipoprotein cholesterol; apoB, apolipoprotein B;; non-HDL-C, non
A1; hsCRP, high-sensitivity C-reactive proteinmore effective in reducing LDL-C, neither of the two
groups reached therapeutic targets.
The 2012 CCS guidelines also recommend alterna-
tive targets including apoB ≤ 0.8 g/L or non-HDL-C ≤
2.6 mmol/L for the treatment of moderate and high
risk patients [20]. Growing evidence indicates that dur-
ing treatment of dyslipidemia, CVD events correlate
more strongly with levels of apoB and non-HDL-C
[22]. ApoB has been suggested as an alternative pri-
mary treatment target in the 2012 CCS guidelines for
individuals with moderate-high CVD [20]. Recently,
Piconi et al have suggested that apoB may predict
ASCVD in HIV-infected populations [23]. In terms of
patients reaching the CCS target of apoB ≤0.80 g/L the
results were similar between groups following 12 weeks of
treatment. When ezetimibe was added to rosuvastatin,th rosuvastatin or rosuvastatin plus ezetimibe
Secondary Targets
g/L non-HDL-C ≤2.6 TG <1.7 mmol/L ApoB:ApoA1
ratio <0.80
hsCRP <2 mg/L
3.25 2.88 0.60 1.72
3.06 1.92 0.55 5.19
- high-density lipoprotein cholesterol; TG, triglycerides; apoA1, apolipoprotein
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compared to 50 % (from 27.8 % at baseline) in patients
treated with rosuvastatin alone. These improvements in
apoB are similar to those reported in a large trial in non-
HIV patients on ezetimibe monotherapy [24]. In addition,
only the ezetimibe treated group had a significant reduc-
tion in non-HDL-C (24 %) as compared to baseline. In
keeping with our findings, others have shown that in HIV-
infected patients combination of statin with ezetimibe was
more effective in lowering non-HDL-C than statin alone
[25]. Borrato et al have shown that treatment of HIV-
infected patients with rosuvastatin 10 mg alone for
16 weeks resulted in a significant reduction of LDL-C as
well as non-HDL-C with 65 % of them achieving thera-
peutic targets [26]. In rosuvastatin monotherapy, we did
not see any significant changes in non-HDL-C. The dif-
ferences between their and our study could be due to
the type of ART, or other confounding factors. In our
study, more patients in the combination group reached
TG <1.7 mmol/L (53.3 %) than the increased dose
group (15 %).
Another marker for cardiovascular risk that has yet to
be thoroughly assessed in the HIV-infected patients is
the apoB/apoA1 ratio. Several studies in the non-HIV
population have shown that increase in this ratio is asso-
ciated with an increased risk of CVD [27, 28]. It has
been suggested that apoB/apoA 1 ratio can be consid-
ered a tool to fine-tune the risk assessment and thus the
targets of therapy [5]. This ratio may be valuable in de-
termining the risk or response to treatment in the HIV-
infected individuals. Our study showed that both treat-
ments resulted in a reduction in apoB/apoA1, albeit
this reduction was statistically significant only in the
ezetimibe-treated patients. However, it should be noted
that among our study patients, an elevated apoB/apoA1
ratio (>0.80) was not prevalent (38 % of patients). This
may be due to the fact that at baseline all these patients
were on 10 mg of rosuvastatin. Accordingly, nearly
every patient reached the apoB/apoA1 target following
12 weeks of treatment. This could suggest that CVD
risk is not greatly elevated in the HIV-infected popula-
tion but as our sample size is small and further investi-
gation into prevalence of elevated apoB/apoA1 ratio in
this population is warranted.
The reported effects of ezetimibe on other lipid
parameters and hsCRP have been variable. Our study re-
sults showed a significant decrease in TC by 19 % in the
ezetimibe plus rosuvastatin group and 10 % in rosuvasta-
tin monotherapy group which is similar to the 10-32 %
reduction previously reported [11, 12, 29]. Also, hsCRP
was lowered by 38 % in rosuvastatin 20 mg group and
10 % in combination of ezetimibe and rosuvastatin
group. In neither group reached statistical significance.
The hsCRP is an inflammatory biomarker, levels ofwhich are associated with risk of CVD. The Emerging
Risk Factors Collaboration has shown an stepwise in-
crease in risk of CVD for hsCRP levels between 0.5 and
20 mg/L with hsCRP > 2.0 mg/L associated with a haz-
ard ratio of CVD of 1.5 [30]. However, this was attenu-
ated after correction for age, sex, diabetes, TG, and
HDL-C. Also, Mendelian randomization studies have
demonstrated that hsCRP is not related to risk of CVD
and not a target of therapy [31, 32]. For HIV-infected
patients, the role of hsCRP may be less clear because the
results could be confounded by other factors such as
other comorbidities and risk factors [5]. We did not see
any significant changes in HDL-C in either group which
is consistent with some studies [12, 14].
Here we showed that the combination of ezetimibe
and rosuvastatin decreased TG (0.62 mmol/L, 24.0 %)
and AIP (0.12, 42.6 %) whereas no such improvement
was seen in the rosuvastatin 20 mg group following
12 weeks of treatment. A novel and not fully investigated
marker of CVD risk in the HIV-infected population is
AIP. The AIP, calculated as logarithm (TG/HDL-C), cor-
relates with size of LDL-C particles, rate of esterification
of plasma cholesterol independent of apoB concentra-
tion [33]. It is used as a predictive marker for atherogenic
risk and cardiovascular risk and is a useful measure of
response to pharmacological intervention [33, 34]. Thus,
AIP may prove to be a useful predictor of risk in this
population given its predictive utility in non-HIV studies
[20] and the fact that it combines two parameters that are
often adversely affected by HIV and ART. At baseline,
60 % of our study cohort were above the high-risk AIP tar-
get of >0.21 [21]. This was significantly improved in the
combination therapy group. The 20 mg rosuvastatin
monotherapy improved AIP by 8 % but this did not reach
statistical significant.
Addition of ezetimibe to rosuvastatin was found to be
well tolerated with an improvement in clinical and bio-
chemical safety profile. As it does not interfere with
CYP450 system and there is low probability of drug-
drug interaction between ezetimibe and HIV drugs.
Limitations
There are several limitations to this study. First this was
a single center study with a small sample size. A 12 week
study duration may be considered short and was not de-
signed to evaluate possible the long-term adverse effects
of ezetimibe. Furthermore, it is not clear whether the
improved reductions in lipid endpoints with ezetimibe
add on therapy will correlate with cardiovascular end-
points when compared to increased statin therapy in this
population. In addition, despite randomization, there
were differences between the groups, especially with
respect to smoking and hypertension.
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We have demonstrated that addition of ezetimibe 10 mg
to rosuvastatin 10 mg is a more effective treatment for
dyslipidemia in HIV-infected population than increasing
dose to 20 mg. Despite lowering of apoB within groups,
there was no statistically significant difference in apoB be-
tween the treatment groups. Ezetimibe was well-tolerated
and no serious adverse events were identified. Trials in
HIV-infected populations are required to assess the ef-
fectiveness of ezetimibe and/or statins on cardiovascu-
lar outcome.
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